Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4Breast 3Gastrointestinal 2Sarcoma 1Other neoplasm 1Other hematologic neoplasm 1Other 1Lymphoid 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Motor Activity 1

Interventions

Paclitaxel 581Carboplatin 528Cisplatin 359Bevacizumab 256pembrolizumab 228Gemcitabine 157liposomal doxorubicin 132Topotecan 131olaparib 129Cyclophosphamide 128Radiotherapy 118Taxes 114Docetaxel 95Brachytherapy 94Drug Therapy 91niraparib 88Doxorubicin 86Surveys and Questionnaires 85Magnetic Resonance Spectroscopy 80Blood Specimen Collection 74Nivolumab 71Specimen Handling 70Hyperthermic Intraperitoneal Chemotherapy 64Biopsy 63fludarabine 57Filgrastim 53Letrozole 50Oxaliplatin 49durvalumab 47Immunoglobulin G 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fitness Trackers × Gynecologic × Clear all
NCT03364673 2023-10-13

Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer

Dana-Farber Cancer Institute

Phase NA Completed
29 enrolled 16 charts
Gynecologic

Motor Activity, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡